View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 31, 2022

Bharat Biotech to start Phase III intranasal Covid-19 booster trial

The company will conduct the trials at nine study centres, including sites in All India Institute of Medical Sciences.

Bharat Biotech has obtained permission from the Drugs Controller General of India (DCGI) to conduct a Phase III clinical trial of the booster doses of its intranasal Covid-19 vaccine.

Named BBV154, the vaccine is being developed by the company under a licencing agreement with Washington University School of Medicine in St Louis, US.

Only the vaccine batches certified by the Central Drugs Laboratory (CDL), Kasauli, will be utilised in the trial.

The trial will be carried out at nine study centres, including sites in All India Institute of Medical Sciences, New Delhi and Bihar. 

A two-dose initial vaccine series, as well as the booster dose regimen of BBV154, will be analysed in the trial.

The booster shot will be analysed in people who already received the Covid-19 vaccines, Covishield and Covaxin, Livemint reported.

Bharat Biotech intends to enrol 5,000 participants with 50% inoculated with Covishield and 50% Covaxin.

An interval of six months will be maintained between the second vaccine dose and booster, sources added.

The multicentre, randomised, open-label study will analyse the safety and immunogenicity of the intranasal vaccine as a booster dose in subjects inoculated with Covid-19 shots approved for use under New Drugs & Clinical Trials Rules, 2019, PTI reported.

Earlier this month, the Subject Experts Committee (SEC) of the DCGI granted approval to the company to commence Phase III and heterologous trials of the Covid-19 intranasal vaccine booster.

Bharat Biotech sought DCGI approval to start the Phase III trial of BBV154 as a booster dose in December.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU